We are live on ! Find out more
SMMT icon

Summit Therapeutics

55 hedge funds and large institutions have $13.6M invested in Summit Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more call options, than puts

Call options by funds: $135K | Put options by funds: $51K

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 5455 (+1)

0.05% more ownership

Funds ownership: 11.32%11.37% (+0.05%)

20% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 20

42% less capital invested

Capital invested by funds: $23.3M → $13.6M (-$9.7M)

Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
16
Reduced
20
Closed
8
Calls
$135K
Puts
$51K
Net Calls
+$84K
Net Calls Change
-$425K

SMMT Hedge Fund Activity: Q4 2021 in Review

55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2021, worth a combined $13.6M — down 42% from $23.3M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SMMT positions and 8 closed out — a net gain of 1 holder — while 16 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $962K. The largest seller was Polar Capital Holdings, cutting an estimated $1.37M.

  • 55 institutional investors held Summit Therapeutics (SMMT) as of Q4 2021, up from 54 in Q3 2021.
  • Funds reported $13.6M of Summit Therapeutics stock for Q4 2021, down 42% quarter-over-quarter.
  • 9 funds opened new Summit Therapeutics positions in Q4 2021 and 8 closed out, a net change of +1 holder.
  • The largest Summit Therapeutics buyer in Q4 2021 was BlackRock, an estimated $962K added.
  • The largest Summit Therapeutics seller in Q4 2021 was Polar Capital Holdings, an estimated $1.37M sold.

Based on aggregated 13F filings for Q4 2021.